secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001104659-24-060536
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M
--------------------------------------------------------------------------------

- Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
- Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.
- YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.
- Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.
- Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/tm2414185d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer